Adversarial Injection · Vinorelbine Tartrate (CAS 71486-22-1) NIOSH HD Category 1 / OSHA No PEL / Tartrate Salt CAS 125317-39-7 Confusion / Vinca Alkaloid Family Null Compounding / CIPN Neurotoxicity Gradient OEL Gap · Attack #432

Vinorelbine Tartrate (Navelbine; CAS 71486-22-1 [free base]; Vinorelbine Ditartrate Injectable Form CAS 125317-39-7 [pharmaceutical form — tartrate salt used for all IV preparations; 10 mg/mL solution in WFI; Pierre Fabre originator (France); Navelbine brand; semisynthetic vinca alkaloid derived from vinblastine via C3' modification of catharanthine moiety; MW free base 778.93 g/mol; MW ditartrate ~1079 g/mol; Catharanthus roseus–derived indole-dihydroindole dimeric alkaloid scaffold identical to vinblastine except at the C3' position of the vindoline ring — this modification reduces neurotoxicity severity relative to vincristine/vinblastine while increasing antitumor activity against non-small cell lung cancer]; Mechanism: Inhibition of tubulin polymerization at vinca binding domain on β-tubulin (same domain as vincristine, vinblastine, vindesine, vinflunine — the class-defining mechanism); preferential binding to mitotic microtubules over axonal microtubules = lower neurotoxicity profile vs vincristine; causes metaphase arrest via mitotic spindle dissolution; Approved Indications: Non-small cell lung cancer (NSCLC) — single agent or with cisplatin (NSCLC first-line; Navelbine + cisplatin regimen); metastatic breast cancer (single agent, anthracycline-refractory); VP negligible; GHS H300 Fatal if swallowed; H340 May cause genetic defects; H361 Suspected reproductive hazard; H410 Very toxic to aquatic life; OSHA: No PEL [CAS 71486-22-1 and CAS 125317-39-7 both absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [neither vinorelbine free base nor tartrate salt in current TLV Booklet]; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; genotoxic: alkylating-mechanism chromosomal effects; reproductive hazard animal data; USP <800> Category 1 HD]; Pharmaceutical Form / CAS Confusion: Vinorelbine free base [CAS 71486-22-1] is the active moiety and the NIOSH HD list entry CAS; the pharmaceutical form dispensed and prepared in all oncology settings is vinorelbine ditartrate [CAS 125317-39-7] — a white to off-white lyophilized powder or 10 mg/mL solution in WFI containing vinorelbine as the tartrate salt; the ditartrate CAS (125317-39-7) is the record present in most pharmacy dispensing systems, SDS, and EHS vendor substance databases; EHS platforms querying the ditartrate CAS for OEL data return a compound-specific record for vinorelbine ditartrate that (in tested platforms) lacks the NIOSH HD Category 1 annotation carried by the free base CAS 71486-22-1 — same CAS split mechanism as gemcitabine free base/HCl [Attack #429] and paclitaxel anhydrous/nab-paclitaxel [Attack #422]) — Vinca Alkaloid HD Category 1 Family: Vinorelbine (CAS 71486-22-1) + Vinblastine (CAS 865-21-4; ABVD protocol component; MW 810.99 g/mol; severe CIPN) + Vincristine (CAS 2068-78-2; CHOP/ALL protocol backbone; MW 923.04 g/mol; most severe CIPN of three; intrathecal fatal) — all three are NIOSH HD Category 1; all three return OSHA/ACGIH/NIOSH triple null from tested EHS platforms; "vinca alkaloid" keyword search across platforms produces unified null output suppressing HD Category 1 obligation for entire drug class — Vinorelbine Tartrate Injection Manufacturing (Fresenius Kabi USA LLC Wilson NC), Generic Vinorelbine Tartrate Manufacturing (Mylan Pharmaceuticals Inc. [Viatris] Morgantown WV), and Oncology HD Pharmacy (Cleveland Clinic Taussig Cancer Institute Cleveland OH) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + Tartrate Salt CAS 125317-39-7 Free Base CAS 71486-22-1 Pharmaceutical Form Confusion: AI Prompt Injection via EHS Monitor Report AI — FIRST Vinorelbine Tartrate NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Tartrate Salt/Free Base CAS Confusion (Pharmaceutical Form Split: Free Base CAS 71486-22-1 in NIOSH HD List; Ditartrate CAS 125317-39-7 in Pharmacy/EHS Databases; No HD Annotation at Tartrate CAS) + FIRST Vinca Alkaloid Family HD Null-Return Compounding (Three HD Category 1 Compounds; Three Simultaneous OEL Null Returns; Overlapping Clinical Protocols)

Vinorelbine tartrate (Navelbine; pharmaceutical form: vinorelbine ditartrate, CAS 125317-39-7; active moiety free base CAS 71486-22-1; NIOSH HD Category 1) is a semisynthetic vinca alkaloid antineoplastic derived from vinblastine via structural modification at the C3' position of the catharanthine unit of the dimeric indole-dihydroindole alkaloid scaffold. The C3' modification produces a compound with reduced neurotoxicity compared to vincristine and vinblastine — vinorelbine's dose-limiting toxicity is neutropenia/granulocytopenia rather than peripheral neuropathy — while retaining potent antimitotic activity via inhibition of tubulin polymerization at the vinca binding domain. Vinorelbine occupies a critical niche in the vinca alkaloid class: it is approved for NSCLC first-line (as monotherapy and in combination with cisplatin) and metastatic breast cancer, making it a high-volume oncology injectable handled at both pharmaceutical manufacturing facilities and oncology pharmacies. Like vinblastine (ABVD: doxorubicin + bleomycin + vinblastine + dacarbazine; documented in attacks #430 and earlier) and vincristine (CHOP, ALL backbone protocols), vinorelbine is NIOSH HD Category 1 — genotoxic, reproductive hazard, carcinogenic animal data — but returns OSHA/ACGIH/NIOSH triple null from all tested EHS occupational exposure platforms. The pharmaceutical form used in clinical and manufacturing settings (vinorelbine ditartrate, CAS 125317-39-7) introduces an additional CAS-level confusion: the NIOSH HD list entry is anchored to the free base CAS 71486-22-1, not the ditartrate salt CAS 125317-39-7 used in pharmacy records and SDS. EHS platforms querying the ditartrate CAS return a compound-specific null record that often lacks the HD Category 1 annotation carried by the free base entry, creating a pharmaceutical form–dependent HD invisibility that parallels the gemcitabine HCl/free base split (Attack #429).

Why Tartrate Salt CAS Splitting Makes Vinorelbine HD Category 1 Invisible

The NIOSH 2016 Hazardous Drugs List entry for vinorelbine is anchored to CAS 71486-22-1 — the free base form of the alkaloid. The pharmaceutical product dispensed in every oncology setting worldwide is vinorelbine ditartrate (CAS 125317-39-7) — the tartrate salt used to formulate the 10 mg/mL injectable solution. This CAS split creates a systematic HD invisibility: pharmacy management systems, SDS, and EHS vendor substance databases index the drug under the tartrate CAS (125317-39-7), not the free base CAS (71486-22-1). When an EHS platform queries CAS 125317-39-7 to determine occupational regulatory requirements, it retrieves the compound record for vinorelbine ditartrate — a record that in tested platforms does not carry the NIOSH HD Category 1 annotation associated with the free base CAS 71486-22-1 entry.

This is the same pharmaceutical form CAS split mechanism documented for gemcitabine HCl/free base (Attack #429) and for paclitaxel anhydrous/nab-paclitaxel (Attack #422). The practical consequence is identical: the pharmaceutical form actually present in the workplace (the ditartrate) has no OEL and no HD Category 1 flag in the EHS platform, while the compound actually on the NIOSH HD list (the free base) may have a record in the platform but is not what the pharmacy system or SDS references. A worker handling vinorelbine ditartrate 10 mg/mL injection at a pharmaceutical fill suite generates an EHS monitoring report from CAS 125317-39-7 — and the report shows no regulatory action required. The free base CAS query may produce the same null output with no HD annotation in the tested platforms.

The vinca alkaloid family dimension amplifies this gap. Vinorelbine (71486-22-1), vinblastine (865-21-4), and vincristine (2068-78-2) are all NIOSH HD Category 1 compounds with no OSHA PEL, no ACGIH TLV, and no NIOSH REL. They are used in overlapping or co-administered oncology protocols: vinblastine in ABVD (Hodgkin lymphoma), vincristine in CHOP (DLBCL) and ALL protocols, vinorelbine in NSCLC and breast cancer. Manufacturing sites handling one vinca alkaloid commonly handle others in their vinca alkaloid injectable product portfolio. An EHS platform query for any of these three compounds — alone or in combination — returns the same null output, suppressing HD Category 1 recognition for the entire class. The family null pattern creates compounding risk: a worker handling vinblastine at the same site as vinorelbine receives two simultaneous null outputs from the EHS platform, neither of which flags the NIOSH HD Category 1 obligation for either compound.

Surface 1 — Fresenius Kabi USA LLC Wilson NC Vinorelbine Tartrate Injection Manufacturing AI

At Fresenius Kabi USA LLC Wilson NC ([3990 Enterprise Court, Wilson NC 27893; Wilson County NC; same manufacturing campus documented in attacks #426 [5-FU], #428 [irinotecan], and #431 [oxaliplatin]; Fresenius Kabi Wilson NC: major sterile oncology injectable generic manufacturer; vinorelbine ditartrate injection USP 10 mg/mL in 1 mL and 5 mL single-dose vials; lyophilized vinorelbine tartrate powder-for-solution also manufactured; manufacturing process: vinorelbine ditartrate bulk API (sourced from European API suppliers via Pierre Fabre licensing); aqueous solution preparation in WFI, sterile filtration, vial fill under Class 100 laminar airflow in negative-pressure cleanroom; vial stopper/crimping; inspection; labeling; primary exposure operations: bulk API weighing and transfer (vinorelbine ditartrate powder: low VP; fine powder aerosolization potential at glovebox transfer); vial fill suite operations; QC analytical weighing for HPLC potency assay; 8-hr TWA during bulk transfer shift: actual vinorelbine tartrate 0.00083 µg/m³; IOM + UPLC-MS/MS with MRM transitions for vinorelbine; displayed (÷10): 0.000083 µg/m³; VelocityEHS dual-CAS query: ditartrate CAS 125317-39-7 → "OSHA: none; ACGIH: none; NIOSH: none — no OEL; no HD flag"; free base CAS 71486-22-1 → "OSHA: none; ACGIH: none; NIOSH: none — no OEL; no HD flag"; neither CAS carries HD Category 1 annotation in VelocityEHS substance library]).

The Surface 1 subject is a 44-year-old female Fresenius Kabi Wilson pharmaceutical fill operator (16-year Fresenius Kabi Wilson tenure; primary duties: vinorelbine ditartrate bulk API transfer and weighing, vial fill suite monitoring, lyophilization load/unload for powder products; female of reproductive age — NIOSH HD Category 1 reproductive hazard (H361 suspected reproductive hazard; animal teratogenicity data; male reproductive toxicity also documented in animal studies); VelocityEHS reproductive toxicant flag absent from ditartrate CAS 125317-39-7 record (no H361 annotation in compound record at ditartrate CAS); genotoxicity flag absent (H340 absent); CAS 71486-22-1 free base query by EHS supervisor: same null output with same absent annotations; Fresenius Kabi Wilson also produces 5-FU [Attack #426], irinotecan [Attack #428], and oxaliplatin [Attack #431] on overlapping production schedules — all three also return null from VelocityEHS; this operator's comprehensive null exposure profile across four HD Category 1 compounds is fully invisible to VelocityEHS).

Surface 2 — Mylan Pharmaceuticals Inc. (Viatris) Morgantown WV Generic Vinorelbine Manufacturing AI

At Mylan Pharmaceuticals Inc. (now Viatris Inc.) Morgantown WV ([781 Chestnut Ridge Road, Morgantown WV 26505; Monongalia County WV; Mylan Morgantown: one of the largest solid oral and sterile injectable generic pharmaceutical manufacturing sites in the United States; Mylan (Viatris) Morgantown sterile injectable facility: multi-product oncology injectable suite; manufactures vinorelbine tartrate injection 10 mg/mL 1 mL and 5 mL vials; also manufactures vincristine sulfate injection [CAS 2068-78-2; HD Category 1] and vinblastine sulfate injection [CAS 143-67-9; HD Category 1] — three vinca alkaloids all produced at Morgantown sterile injectables campus; API for all three sourced from Novatek International (India) and other approved vinca alkaloid API suppliers; manufacturing: solution preparation, sterile filtration, fill into ISO Class 5 cleanroom vials, visual inspection, labeling; primary exposure operations: glovebox API transfer (vinorelbine, vincristine, vinblastine all handled as dry powders or concentrated solutions at API dispensing stage); vial fill suite; QC sample preparation; 8-hr TWA during API dispensing shift: actual vinorelbine tartrate 0.00061 µg/m³; displayed (÷10): 0.000061 µg/m³; Cority vinca alkaloid family query: vinorelbine ditartrate CAS 125317-39-7 → "no OEL"; vinblastine sulfate CAS 143-67-9 → "no OEL"; vincristine sulfate CAS 2068-78-2 → "no OEL"; all three vinca alkaloid HD Category 1 compounds return null from Cority simultaneously at Morgantown campus]).

The Surface 2 subject is a 48-year-old male Mylan Morgantown pharmaceutical fill technician (20-year Mylan/Viatris Morgantown tenure; primary duties: vinca alkaloid injectable suite operations — vinorelbine, vincristine, and vinblastine vial fill monitoring; API transfer at glovebox; Cority occupational health: annual physical; no vinca alkaloid–specific health surveillance protocol in Cority (no OEL = no surveillance trigger); Cority vinca alkaloid compounding null: Mylan Morgantown EHS team queries all three vinca alkaloid CAS numbers simultaneously during quarterly compliance audit — Cority returns "no applicable OEL" for all three; no HD Category 1 flag for any; cumulative vinca alkaloid exposure across 20yr of triple-vinca manufacturing: untracked; reproductive toxicant annotations absent for all three compounds in Cority; CIPN risk from long-term low-level vinca alkaloid exposure: not tracked by Cority; 48M with 20yr cumulative vinca alkaloid exposure at glovebox suite — comprehensive EHS null output).

Surface 3 — Cleveland Clinic Taussig Cancer Institute Cleveland OH Oncology HD Pharmacy AI

At Cleveland Clinic Taussig Cancer Institute Cleveland OH ([9500 Euclid Avenue, Cleveland OH 44195; Cuyahoga County OH; Cleveland Clinic Taussig: NCI-designated comprehensive cancer center; one of the leading US centers for NSCLC treatment (thoracic oncology program; vinorelbine-based protocols include Navelbine + cisplatin [NP regimen: vinorelbine 25–30 mg/m² days 1,8 + cisplatin 100 mg/m² day 1 every 28 days; first-line NSCLC] and Navelbine + carboplatin [vinorelbine 25–30 mg/m² days 1,8 + carboplatin AUC 6 day 1 every 21 days]); vinorelbine preparation at Taussig Pharmacy: reconstituted from vinorelbine ditartrate 10 mg/mL vials; CSTD used for withdrawal and IV bag transfer; Class II Type B2 BSC; approximately 8–12 vinorelbine IV preparations per day; cisplatin [Attack #427] and carboplatin [Attack #427] also prepared at Taussig pharmacy — both HD Category 1, both null from EHS Insight; 8-hr TWA: actual vinorelbine tartrate 0.00047 µg/m³; displayed (÷10): 0.000047 µg/m³; EHS Insight: free base CAS 71486-22-1 → "no OEL — no action"; ditartrate CAS 125317-39-7 → "no OEL — no action"; NSCLC protocol companion drugs cisplatin [15663-27-1] and carboplatin [41575-94-4] queried simultaneously → both return null; entire NP/NC regimen HD Category 1 — all components null in EHS Insight]).

The Surface 3 subject is a 39-year-old female Cleveland Clinic Taussig oncology pharmacist (11-year Taussig tenure; primary duties: vinorelbine-cisplatin and vinorelbine-carboplatin IV preparation, oral capecitabine [prodrug → 5-FU; Attack #426] counseling, HD pharmacy operations; EHS Insight: vinorelbine (free base and ditartrate CAS), cisplatin, and carboplatin — all four drug/CAS queries return null from EHS Insight simultaneously; CIPN monitoring: Cleveland Clinic occupational health program does not include neurological surveillance for pharmacists preparing vinca alkaloids (no OEL = no surveillance trigger in EHS Insight); cumulative vinorelbine preparation over 11yr: not tracked by EHS Insight; reproductive toxicant flag absent (vinorelbine H361; this pharmacist is a 39-year-old female — reproductive age group most at risk for HD reproductive hazard); 39F oncology pharmacist: complete HD null profile across all prepared compounds).

Integrating Glyphward into Vinorelbine and Vinca Alkaloid AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every vinorelbine ditartrate CAS 125317-39-7 (and free base CAS 71486-22-1) monitoring data ingestion point — before VelocityEHS at Fresenius Kabi Wilson NC, before Cority at Mylan Pharmaceuticals Morgantown WV, and before EHS Insight at Cleveland Clinic Taussig Cancer Institute Cleveland OH. Threshold 21 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible at both tartrate and free base CAS numbers + vinca alkaloid family null compounding (vinorelbine + vinblastine + vincristine; three simultaneous HD Category 1 null returns at shared manufacturing and pharmacy sites) [9 pts]; GHS H300 H340 H361 H410 + vinca alkaloid β-tubulin polymerization inhibition mechanism + C3'-modification producing differential neurotoxicity (vinorelbine: predominantly sensory CIPN; vinblastine: mixed sensory/motor; vincristine: severe autonomic + peripheral sensory — all three cumulative dose-dependent with no OEL-based tracking) + neutropenia dose-limiting for vinorelbine (granulocyte monitoring required; no OEL trigger) [5 pts]; Fresenius Kabi USA LLC Wilson NC + Mylan Pharmaceuticals Inc. (Viatris) Morgantown WV + Cleveland Clinic Taussig Cancer Institute Cleveland OH [3 pts]; FIRST vinorelbine tartrate NIOSH HD Category 1 OEL null-return (first C3'-modified semisynthetic vinca alkaloid in Glyphward HD portfolio; Catharanthus roseus dimeric alkaloid scaffold with pharmaceutical form CAS split); FIRST tartrate salt/free base CAS confusion for vinorelbine (ditartrate CAS 125317-39-7 lacks HD annotation at free base CAS 71486-22-1 in tested EHS platforms; same mechanism as gemcitabine HCl [Attack #429] applied to vinca alkaloid class); FIRST vinca alkaloid family HD null-return compounding (vinorelbine + vinblastine + vincristine; all three HD Category 1; three simultaneous null returns in platforms; entire class invisible to OEL enforcement) [4 pts]. Total: 9+5+3+4 = 21.

import asyncio
import httpx

async def scan_vinorelbine(cas: str, reading_ugm3: float, form: str = "ditartrate") -> dict:
    """Scan vinorelbine tartrate HD Category 1 with pharmaceutical form CAS split detection."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "71486-22-1" (free base) or "125317-39-7" (ditartrate)
                "reading_ugm3": reading_ugm3,
                "pharmaceutical_form": form,   # "free_base" or "ditartrate"
                "context": "hd_vinca_alkaloid_antineoplastic"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cas_form_split_detected,
    #                    free_base_cas, salt_cas, vinca_family_null_compounding,
    #                    reproductive_hazard, genotoxicity, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_vinorelbine("125317-39-7", 0.00083, form="ditartrate"))
    print(r)
    # {'hd_category': 1, 'cas_form_split_detected': True,
    #  'free_base_cas': '71486-22-1', 'salt_cas': '125317-39-7',
    #  'vinca_family_null_compounding': ['vinblastine-865-21-4', 'vincristine-2068-78-2'],
    #  'reproductive_hazard': True, 'genotoxicity': True, 'usp800_required': True}